amgen meritade glp-1 activity duration aims to enter weight loss drug market with a new approach AMGEN ANNOUNCES ROBUST WEIGHT LOSS

If you draw 1.8 mL instead of 2.0 mL, your actual concentration will be 2.78 mg/mL instead of the expected 2.5 mg/mL

doi: 10.1517/14656566.2013.824966 18 NauckMAQuastDRWefersJMeierJJ

Distribute Throughout the Day : Rather than loading all your protein into one meal, spread it across three meals

The sample size was relatively small

STEP-1 Trial (Semaglutide 2.4 mg, N=1,961) The STEP-1 trial published in the New England Journal of Medicine reported that among participants receiving semaglutide 2.4 mg subcutaneously once weekly, nausea occurred in 44.2%, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.1%, compared to 16.0%, 15.9%, 6.8%, and 11.1% with placebo, respectively [3]